Publications by authors named "Xinjing Ma"
Article Synopsis
- A phase 3 study showed that combining camrelizumab with chemotherapy significantly improved progression-free survival in patients with advanced non-squamous non-small-cell lung cancer compared to chemotherapy alone.
- After 5 years, overall survival rates were 31.2% for those receiving camrelizumab and chemotherapy versus 19.3% for those on chemotherapy alone, indicating a substantial benefit.
- Patients who completed two years of treatment with camrelizumab had an impressive 5-year overall survival rate of 84.3%, reinforcing its effectiveness and safety as a first-line therapy for this cancer type.
Introduction: In CameL phase 3 study (ClinicalTrials.gov: NCT03134872), addition of camrelizumab to first-line chemotherapy significantly improved the progression-free survival in patients with stages IIIB to IV nonsquamous NSCLC. Here, we present outcomes after a minimum follow-up of 43.
View Article and Find Full Text PDFBackground: Second-line treatment options for small cell lung cancer (SCLC) are limited. Preclinical research shows that inhibition of poly (ADP-ribose) polymerase (PARP) could upregulate programmed death-ligand 1 (PD-L1), and thus render cancer cells more sensitive to immune checkpoint inhibitors. This study investigated the tolerability, safety, and preliminary antitumor activity of fuzuloparib (a PARP inhibitor) plus SHR-1316 (a PD-L1 inhibitor) for relapsed SCLC.
View Article and Find Full Text PDFArticle Synopsis
- A study conducted in China examined sex differences in the natural history of HPV infections among 4687 participants aged 18-55, finding that both men and women had similar rates of oncogenic HPV infections.
- Men had a higher incidence of HPV-6/11 infections compared to women, while younger women (18-25) experienced more infections than older women.
- Men cleared oncogenic infections more effectively than women, leading to recommendations for sex-specific vaccination strategies against both oncogenic and nononcogenic HPV types.
To determine the incidence of anogenital warts (AGWs) in the Chinese general population, we compared the data from a prospective study and from the National Notifiable Disease Report System (NNDRS). A cohort study including 2378 women and 2309 men aged 18-55 years old enrolled from Liuzhou, China, was conducted with three scheduled visits at 6-month intervals from May 2014 to March 2016. And, a questionnaire survey was performed to collect the diagnosis history of AGWs at the enrollment visit.
View Article and Find Full Text PDF